[1]
“Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Analysis of Mental Health and Associated Disorders”, J of Skin, vol. 7, no. 6, p. s300, Nov. 2023, doi: 10.25251/skin.7.supp.300.